CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...